Daniel Hollern

Daniel Hollern is an Assistant Professor at the Salk Institute for Biological Studies, where he leads the Hollern Lab within the NOMIS Center for Immunobiology and Microbial Pathogenesis. His research focuses on understanding tumor-immune cell interactions, with particular emphasis on B cells in cancer immunity.

Dr. Hollern's educational background includes a PhD in Cell and Molecular Biology from Michigan State University, postdoctoral training at the University of North Carolina, and a Bachelor of Science in Biology from Grand Valley State University.

Hollern's research interests center on cancer immunology, specifically investigating how B cells contribute to anti-tumor immune responses. His lab has made groundbreaking discoveries showing that B cells are key regulators of response to immune checkpoint inhibitors, particularly in triple-negative breast cancer. His work demonstrates that patients with tumor-infiltrating B cells have higher response rates to chemotherapy and immunotherapy. The lab's research explores B cell interactions with CD4+ T cells, antibody production against tumor cells, and the mechanisms by which B cells drive curative responses to immunotherapy. Current investigations focus on leveraging B cells therapeutically to improve cancer treatment outcomes.

Analysis of Dr. Hollern's recent publications reveals a consistent focus on B cell immunology in cancer, with particular emphasis on triple-negative breast cancer. His work spans basic immunological mechanisms, translational applications, and clinical implications of B cell activity in tumor microenvironments. The research demonstrates how B cells interact with other immune components like T follicular helper cells and interleukin 21 to mediate anti-tumor responses.

• 2019 Joseph Pagano Award
• 2015 NIH NCI F32 Ruth L. Kirschstein National Research Service Award
• 2014 NIH NCI F31 Ruth L. Kirschstein National Research Service Award
• 2014 Aitch Foundation Award

The Hollern Lab maintains a strong focus on mentoring and collaboration, emphasizing diversity, inclusion, and equitable scientific practices. The lab culture prioritizes building a supportive environment for tackling complex cancer research questions through interdisciplinary approaches. Dr. Hollern's research program represents a significant contribution to understanding how to harness the immune system, particularly B cells, to develop more effective cancer treatments with long-term disease control.